Advice for Investors Entering Weight-Loss Market
In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, shares advice for investors and financiers who are considering entering the weight-loss medication market.
What advice do you have for investors and financiers who are considering entering the weight-loss medication market?
First of all, don't believe the hype. It's calmed down a little now. But remember, when last summer when you had, you know, crazy things like news would come out and the stock of fast food companies would go down? You know, nothing is that revolutionary. So that's calmed down a little bit. But then I hearken back to what I was saying, there's so many companies in this field, not all of them come yet. So, I think you have to really do your homework and to pick and choose who are going to be the winners. And unlikely that you're going to have, you know, a small new company get established, you may have some of these companies that are small and are working on products, they will link up with the established players, or Lilly or novo, or one of the bigger drug companies that are eager to get into this market. And you've already seen several examples of that happening. So, there will be some winners and there'll be a lot of losers. So, if you're an investor, do your homework well. Or makes or place a lot of bets and hope that a few of them pay off.
Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support
May 7th 2025Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
